Veteran private equity investor and corporate executive, Richard Tomes has led buyouts and growth investments across industrials and healthcare, focusing on operational improvement and value creation. He brings board-level experience, deal sourcing, and portfolio management skills from multi-decade roles at mid-market firms and operating companies. Educated in finance and management, he is known for hands-on restructuring and strategic M&A execution that drives operational turnarounds.
Veteran private equity investor and corporate executive, Richard Tomes has led buyouts and growth investments across industrials and healthcare, focusing on operational improvement and value creation. He brings board-level experience, deal sourcing, and portfolio management skills from multi-decade roles at mid-market firms and operating companies. Educated in finance and management, he is known for hands-on restructuring and strategic M&A execution that drives operational turnarounds.
Targets control-oriented, mid-market buyouts and growth equity with a bias to industrials and healthcare, prioritizing operational improvement and margin expansion through hands-on restructuring and strategic M&A. Investment decisions emphasize board-level governance, rigorous due diligence on cash‑flow upside, and clear operational KPIs tied to value creation. Capital allocation favors staged equity and debt-enhancing structures to align incentives and limit downside. Typical holding periods are medium-to-long, focused on driving scalable EBITDA growth and exit optionality.
Targets control-oriented, mid-market buyouts and growth equity with a bias to industrials and healthcare, prioritizing operational improvement and margin expansion through hands-on restructuring and strategic M&A. Investment decisions emphasize board-level governance, rigorous due diligence on cash‑flow upside, and clear operational KPIs tied to value creation. Capital allocation favors staged equity and debt-enhancing structures to align incentives and limit downside. Typical holding periods are medium-to-long, focused on driving scalable EBITDA growth and exit optionality.
| Trades 839 | Longs Won 525/839 62% | Profit Factor 5.65 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $146,307.24 |
| Average Win $77,296.17 | Best Trade (Jul 14) $2.04M | Sharpe Ratio -9.93 |
| Average Loss -$22,882.35 | Worst Trade (Jul 17) -$402,393.44 | Z-Score 2.99 (99.72%) |
| Commissions $0 | Avg. Trade Length 9m 2w 5d | Expectancy $39,803.85 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 5,952 | 5,357 | 4,762 | 4,167 | 3,571 | 2,976 | 2,381 | 1,786 | 1,190 | 595 |